FDA Approves Ziftomenib for Relapsed or Refractory Acute Myeloid Leukaemia with a NPM1 Mutation By Ogkologos - November 20, 2025 218 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the KO-MEN-001 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Poherdy Whole-Genome Sequencing Meets Diagnostic Requirements in Routine Practice for Patients with Solid Cancers FDA Approves Relacorilant with nab-Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer MOST POPULAR Scientists find cells in centre of tumours are most likely to... May 18, 2021 El cáncer en mi comunidad: Cómo superar las desigualdades en la... January 3, 2023 How People With Cancer Can Make the Most of Televisits December 4, 2020 Pink Van Makes the Rounds Throughout Rural New Zealand to Offer... February 24, 2021 Load more HOT NEWS Initial Results of the CanScreen5, an Authentic Data Repository for Cancer... Patritumab Deruxtecan Demonstrates a Manageable Safety Profile and Durable Efficacy in... How My Advanced Colorectal Cancer Diagnosis Led Me to Patient Advocacy Favourable Results of Patritumab Deruxtecan in Patients with Leptomeningeal Metastatic Disease...
